Table 2.
Tumor characteristics for the Discovery and Validation cohorts, respectively, separated into columns for cases and controls. Stage and histology are only reported for cases. Continuous variables are reported as median (interquartile range, IQR), and categorical variables are reported as fraction (percentage, %). As a result of rounding, not all categories add up to 100%.
| Discovery Cohort | Validation Cohort | |||
|---|---|---|---|---|
| Variable | Cases (n = 67) |
Controls (n = 34) | Cases (n = 50) |
Controls (n = 45) |
| Tumor on CT scan | 60 | 11 | 50 | 28 |
| Largest mean diameter, mm | 27 (19–47) | 19 (13–22) | 42 (23–70) | 22 (14–50) |
| Localization | - | - | - | - |
| Central | 19/60 (28%) | 3/11 (27%) | 12/50 (24%) | 6/28 (21%) |
| Intermediate | 15/60 (22%) | 2/11 (18%) | 22/50 (44%) | 11/28 (39%) |
| Peripheral | 26/60 (39%) | 6/11 (55%) | 16/50 (32%) | 11/28 (39%) |
| Confirmed lung cancer | ||||
| Stage | - | - | - | |
| 1 | 18/65 (28%) | - | 5/48 (10%) | - |
| 2 | 7/65 (11%) | - | 14/48 (29%) | - |
| 3 | 16/65 (25%) | - | 16/48 (33%) | - |
| 4 | 24/65 (37%) | - | 13/48 (27%) | - |
| Histology | - | - | ||
| Adenocarcinoma | 32/67 (48%) | - | 34/50 (68%) | - |
| Squamous cell carcinoma | 22/67 (33%) | - | 8/50 (16%) | - |
| Small cell carcinoma | 6/67 (9%) | - | 3/50 (6%) | - |
| Other non-small cell lung cancer | 7/67 (10%) | - | 5/50 (10%) | - |